参考文献/References:
[1] 王悦，史利克，张鲁涛，等．医院获得性下呼吸道感染病原菌分布及耐药性分析[J]．临床荟萃，112 现代检验医学杂志 第35 卷 第4 期 2020 年7 月 J Mod Lab Med, Vol. 35, No. 4, July. 20202015, 30（11）: 1269-1272． WANG Yue ，SHI Like， ZHANG Lutao, et al.Distribution of pathogens and resistance analysis ofhospital-acquired lower respiratory tract infection[J].Clinical Focus, 2015, 30（11）: 1269-1272.
[2] DAYAN G H, MOHAMED N, SCULLY I, et al. Staphylococcusaureus: the current state of disease, pathophysiologyand strategies for prevention , pathophysiologyand strategies for prevention[J]. Expert Review ofVaccines, 2016, 15(11): 1373-1392.
[3] NORDMANN P, NAAS T, FORTINEAU N, et al.Superbugs in the coming new decade; multidrug resistanceand prospects for treatment of Staphylococcusaureus, Enterococcus spp.and Pseudomonas aeruginosain 2010[J]. Current Opinion in Microbiology, 2007,10(5): 436-440.
[4] HU Jian，MA Xiaoxue，TIAN Yuan, et al. Reducedvancomycin susceptibility found in methicillin resistantand methicillin sensitive Staphylococcus aureus clinicalisolates in Northeast China[J]. PLoS One, 2013, 8(9):e73300.
[5] HIRAMATSU K，HANAKI H，INO T，et a1．Methicillin-resistant Staphylococcus aureus clinicalstrain with reduced vancomycin susceptibility[J]. JAntimicrob Chemother，1997, 40(1):135-136.
[6] Centers for Disease Control and Prevention.Staphylococcus aureus resistant to vancomycin--UnitedStates, 2002 [J]. Morbidity and Mortality WeeklyReport, 2002, 51（26）: 565-567.
[7] Centers for Disease Control and Prevention.Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002 [J]. Morbidity and mortalityWeekly Report, 2002, 51（40）: 902.
[8] 王敬华，马筱玲，濮跃晨，等．Hetero-VRS 检测方法的建立及其临床意义[J]．现代检验医学杂志,2003, 18（5）: 3-6． WANG Jinghua，MA Xiaoling，PU Yuechen，etal.To develop a new method for hetero-VRS isolationand its use in clinical laboratory[J]．Journal of ModernLaboratory Medicine, 2003, 18（5）: 3-6.
[9] HIRAMATSU K, ARITAKA N, HANAKI H, et al.Dissemination in Japanese hospitals of strains ofStaphylococcus aureus heterogeneously resistant tovancomycin[J]. Lancet, 1997, 350(12): l670-l673.
[10] FRIDKIN S K. Vancomycim intermediate and-resistantStaphylococcus aureus:What the infectious diseasespecialist needs to know[J]. Clin Inf Dis, 2001, 32(1):108-115.
[11] DMITRIEV B, TOUKACH F V, HOLST O, et al.Tertiary structure of Staphylococcus aureus cell wallmurein[J]. Journal of Bacteriology, 2004, 186(21):7141-7148.
[12] VAN HAL S J, LODISE T P, PATERSON D L, et al.The clinical significance of vancomycin minimuminhibitory concentration in Staphylococcus aureusinfections: a systematic review and meta analysis[J].Clinical Infectious Diseases, 2012, 54(6): 755-771.
[13] CUI Longzhu, MA Xiaoyue, SATO K, et al. Cellwall thickening is a common feature of vancomycinresistance in Staphylococcus aureus[J]. Journal ofClinical Microbiology, 2003, 41(1): 5-14.
[14] 马筱玲．万古霉素敏感性减低的金黄色葡萄球菌[J].中华检验医学杂志, 2004, 27（9）: 620-622． MA Xiaoling. Staphylococcus aureus with reducedvancomycin sensitivity[J]．Chinese Journal ofLaboratory Medicine, 2004, 27（9）: 620-622.
[15] HIRAMATSU K. Vancomycin-resistant Staphylococcusaureus: a new model of antibiotic resistance [J]．Lancet Infectious Diseases,2001,1（3）:147-155.